Aafia Chaudhry

Aafia Chaudhry M.D. is a founding partner at Noesis LLC, an investment-management firm focused on the pharmaceutical and biotechnology sectors. She originally trained in general surgery prior to transitioning into the health-care industry. Aafia has been an active life-sciences investor for the past nine years and is an expert in pharmaceutical life-cycle management strategy. She was formerly president of 81qd, a strategic data-analytics consultancy, and most recently served as vice president of strategic market planning at WebMD Health Corp.

Recent Articles By The Author

Chelsea Therapeutics: Northera FDA Panel Live Blog

Chelsea Therapeutics: Northera FDA Panel Live Blog

A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.

Unigene Faces Do-or-Die FDA Panel Tuesday

Unigene Faces Do-or-Die FDA Panel Tuesday

An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.

Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied

Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied

Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.

Depomed Bear Case: FDA Panel Will Ding Serada

Depomed Bear Case: FDA Panel Will Ding Serada

New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.